



(51) International Patent Classification:  
C12N 15/86 (2006.01)

(21) International Application Number:  
PCT/US2022/078092

(22) International Filing Date:  
14 October 2022 (14.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
63/256,447 15 October 2021 (15.10.2021) US

(71) Applicant: INTERIUS BIOTHERAPEUTICS, INC.  
[US/US]; 3401 Grays Ferry Avenue, Building 200, Suite  
300, Philadelphia, Pennsylvania 19146 (US).

(72) Inventors: JOHNSON, Philip R.; 3401 Grays Ferry Avenue,  
Building 200, Suite 300, Philadelphia, Pennsylvania 19146 (US). PELUSO, Richard W.; 3401 Grays Ferry Avenue,  
Building 200, Suite 300, Philadelphia, Pennsylvania 19146 (US). RUSSELL, Ronnie M.; 3401 Grays Ferry Avenue,  
Building 200, Suite 300, Philadelphia, Pennsylvania 19146 (US).

enue, Building 200, Suite 300, Philadelphia, Pennsylvania 19146 (US). SCHNEPP, Bruce C.; 3401 Grays Ferry Avenue, Building 200, Suite 300, Philadelphia, Pennsylvania 19146 (US).

(74) Agent: SCOLNICK, Daniel M. et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: EBOLA PSEUDOTYPED VECTORS AND METHODS OF USE THEREOF




FIG. 1A

(57) Abstract: The present embodiments provide methods and compositions for pseudotyping viral vectors. Also provided are methods and compositions for creating targeting moiety fused viral glycoproteins. Also provided herein are methods of treating a disease in a subject in need thereof using the compositions provided for herein. Also provided are methods of delivering a molecule of interest to a target cell using the compositions provided for herein.

[Continued on next page]

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*